Oliver Engert Buys 2,458 Shares of Enovis (NYSE:ENOV) Stock

Key Points

• Insider buying increased: Oliver Engert purchased 2,458 Enovis shares for nearly $50,000, raising his stake by 4.58% to 56,098 shares. He also recently bought an additional 5,140 shares, while CEO Damien McDonald purchased roughly $249,620 worth of stock.
• Shares declined sharply: ENOV fell 4.2% to $18.58, near its 52-week low of $18.52 and well below its 50-day and 200-day moving averages. Despite the pressure, Enovis exceeded quarterly earnings and revenue expectations.
• Analyst sentiment remains generally positive: Ten analysts rate the stock a Buy, contributing to a “Moderate Buy” consensus and an average price target of $40.38, although several firms recently lowered their targets.

Enovis Corporation (NYSE:ENOV - Get Free Report) insider Oliver Engert acquired 2,458 shares of Enovis stock in a transaction on Wednesday, September 2nd. The stock was purchased at an average cost of $20.32 per share, with a total value of $49,946.56. Following the purchase, the insider directly owned 56,098 shares of the company's stock, valued at approximately $1,139,911.36. This trade represents a 4.58% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link.

Oliver Engert also recently made the following trade(s):

• On Thursday, September 3rd, Oliver Engert acquired 5,140 shares of Enovis stock. The shares were purchased at an average price of $19.46 per share, with a total value of $100,024.40.
• On Monday, June 15th, Oliver Engert bought 1,000 shares of Enovis stock. The shares were purchased at an average cost of $20.92 per share, for a total transaction of $20,920.00.
• On Thursday, June 11th, Oliver Engert bought 1,200 shares of Enovis stock. The stock was purchased at an average price of $21.62 per share, for a total transaction of $25,944.00.
• On Wednesday, June 10th, Oliver Engert purchased 1,000 shares of Enovis stock. The stock was acquired at an average cost of $23.00 per share, with a total value of $23,000.00.

Enovis Stock Down 4.2%

ENOV stock traded down $0.82 during midday trading on Friday, reaching $18.58. 1,886,327 shares of the company's stock traded hands, compared to its average volume of 1,200,013. The company has a market cap of $1.07 billion, a price-to-earnings ratio of -0.96 and a beta of 1.31. The firm's fifty day moving average price is $25.50 and its 200-day moving average price is $24.20. The company has a quick ratio of 1.00, a current ratio of 1.98 and a debt-to-equity ratio of 0.84. Enovis Corporation has a 52 week low of $18.52 and a 52 week high of $34.28.

Enovis (NYSE:ENOV - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, beating analysts' consensus estimates of $0.85 by $0.05. The firm had revenue of $582.78 million for the quarter, compared to analyst estimates of $581.84 million. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The business's quarterly revenue was up 3.2% compared to the same quarter last year. During the same period last year, the firm earned $0.79 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, sell-side analysts forecast that Enovis Corporation will post 3.15 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Enovis

A number of institutional investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP lifted its position in Enovis by 1.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,971,545 shares of the company's stock worth $90,156,000 after buying an additional 51,201 shares during the last quarter. Rubric Capital Management LP bought a new position in shares of Enovis in the third quarter worth approximately $83,435,000. Paradigm Capital Management Inc. NY grew its holdings in shares of Enovis by 70.2% in the first quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company's stock worth $40,420,000 after purchasing an additional 732,917 shares during the last quarter. River Road Asset Management LLC increased its stake in shares of Enovis by 3.2% in the fourth quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company's stock worth $39,621,000 after buying an additional 46,289 shares during the period. Finally, Private Management Group Inc. raised its holdings in Enovis by 38.8% during the 2nd quarter. Private Management Group Inc. now owns 1,365,082 shares of the company's stock valued at $28,257,000 after buying an additional 381,705 shares during the last quarter. Institutional investors own 98.45% of the company's stock.

Enovis News Roundup

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: CEO Damien McDonald bought 13,035 shares for approximately $249,620, increasing his stake by 5.57%. A substantial open-market purchase by the chief executive may signal confidence that the recent selloff has pushed the stock below its perceived value. SEC filing on CEO purchase
• Positive Sentiment: Insider Oliver Engert purchased 5,140 shares worth approximately $100,024, raising his ownership by 9.16%. The additional insider buying provides another potential confidence signal for investors. SEC filing on insider purchase
• Positive Sentiment: Zacks upgraded Enovis to Rank #2, or “Buy,” citing improving earnings prospects. Analysts’ upward earnings revisions and technically oversold conditions also suggest the possibility of a near-term trend reversal. Zacks Buy rating article
• Positive Sentiment: Canaccord Genuity maintained a Buy rating on ENOV, reinforcing the view that the selloff may have created an attractive entry point. Canaccord Genuity rating article
• Neutral Sentiment: A Q2 comparison with other specialty medical-device companies provides industry context, but the item does not identify a new material change to Enovis’ outlook. Q2 earnings comparison
• Negative Sentiment: Wells Fargo lowered its ENOV price target to $33, while Citizens JMP reduced its target to $47. Although both targets remain above the current trading range, the cuts indicate more cautious valuation assumptions and may weigh on sentiment. Wells Fargo price-target article Citizens JMP price-target article

Analysts Set New Price Targets

ENOV has been the topic of a number of recent analyst reports. Evercore set a $32.00 price target on shares of Enovis in a research report on Monday, July 6th. Wall Street Zen cut shares of Enovis from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. BTIG Research cut their price target on shares of Enovis from $40.00 to $36.00 and set a "buy" rating on the stock in a report on Tuesday. Wells Fargo & Company dropped their price objective on Enovis from $39.00 to $33.00 and set an "overweight" rating on the stock in a research note on Wednesday. Finally, UBS Group reissued a "buy" rating and set a $51.00 price objective (up from $50.00) on shares of Enovis in a report on Tuesday, July 28th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Enovis presently has an average rating of "Moderate Buy" and a consensus price target of $40.38.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source